Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HS-10365 in advanced solid tumors with RET alterations
CTR20212581Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hs-10365 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), thyroid cancer, sponsored by Hengrui Therapeutics. Started Nov 2021; status: active.
02
Drugs
hs-10365
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)thyroid cancer
Beyond the preview
Go deeper on CTR20212581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212581.